FDA employees are experiencing frustration and anxiety as the agency moves to increase in-person work, mandating that many staff return to the office for at least three days a week. This decision reverses previous pandemic-era remote work policies and clashes with the Biden administration’s broader guidance allowing for more flexible work arrangements.
The move impacts a significant portion of the FDA workforce, particularly those in headquarters and field offices. Employees cite concerns about the timing, as the mandate coincides with rising COVID-19 cases, influenza, and RSV, raising fears about potential illness and disruption to family lives. They also point to the lack of scientific evidence supporting the decision to increase in-person work, especially given the FDA’s own recommendations for mitigating respiratory illnesses.
Furthermore, employees are questioning the rationale for the return-to-office policy, arguing that productivity and morale have been high during remote work. Concerns are also mounting regarding the FDA’s ability to accommodate the increased number of employees returning to the office, citing crowded workspaces, limited parking, and insufficient sanitation measures. Union representatives are actively engaging with the agency to address these concerns and advocate for more flexible work options that prioritize employee safety and well-being.
find the original article here: https://www.yahoo.com/news/fda-staff-return-crowded-offices-210248035.html